|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-8-28
|
|
pubmed:abstractText |
Combined paclitaxel and carboplatin is a standard regimen for inoperable non-small cell lung cancer (NSCLC). Although an every-3-week schedule is common, weekly paclitaxel is clinically effective for various cancers. A Phase I clinical trial was conducted to determine maximum-tolerated doses (MTDs) for weekly combined paclitaxel and carboplatin, and to evaluate anti-tumor response, toxicity and pharmacokinetics of paclitaxel in patients with inoperable NSCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1465-3621
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
569-75
|
|
pubmed:meshHeading |
pubmed-meshheading:19520687-Aged,
pubmed-meshheading:19520687-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19520687-Carboplatin,
pubmed-meshheading:19520687-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19520687-Dose-Response Relationship, Drug,
pubmed-meshheading:19520687-Female,
pubmed-meshheading:19520687-Humans,
pubmed-meshheading:19520687-Lung Neoplasms,
pubmed-meshheading:19520687-Male,
pubmed-meshheading:19520687-Maximum Tolerated Dose,
pubmed-meshheading:19520687-Middle Aged,
pubmed-meshheading:19520687-Paclitaxel,
pubmed-meshheading:19520687-Prognosis,
pubmed-meshheading:19520687-Prospective Studies,
pubmed-meshheading:19520687-Survival Rate,
pubmed-meshheading:19520687-Tissue Distribution,
pubmed-meshheading:19520687-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
|
|
pubmed:affiliation |
Yokohama Municipal Citizen's Hospital, Yokohama, Japan. knaoki@pg7.so-net.ne.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
